In a randomized double-blind placebo controlled study of 27 patients with acute ischemic stroke, the effect on regional CMRglc (rCMRglc) of the calcium channel blocking agent nimodipine administered in addition to routine treatment was investigated. Follow ing computed tomography-supported diagnosis of focal ischemia in the middle cerebral artery territory, positron emission tomography (P ET) of 2-[18F] fluoro-2-deoxY-D-glucose (FDG) was performed, and the pa
tients were entered into the study within 48 h after onset of symptoms, randomly receiving either nimodipine (2 mg/h constant i.v. infusion for 5 days, 120 mg/day orally for another 16 days) or carrier/placebo. FDG PET was repeated after completion of therapy. The clinical course was followed during the treatment period and for 6 months after the stroke, using the Mathew Score for early and the Barthel Index for late assessment. During that observation period, five patients died in the nimodipine group and four in the control group. Subsequently, the code was broken, and the clinical and PET data were analyzed in relation to treatment assignment, with the nimodipine group comprising 11 and the control group 12 eligible cases. The two groups were similar with respect to age and sex distribution, initial clinical deficit, and in farct size and location. While the infarct rCMRglc showed comparable slight increases over time in both groups, the Common therapeutic strategies in ischemic stroke are aimed at improving blood flow, increas ing ischemic tolerance, or ameliorating biochemical or other secondary mechanisms contributing to the metabolic changes in the other evaluated regions (contra lateral infarct mirror region, ipsi-and contralateral cere bral gray matter, contra-and ipsilateral cerebellar hemi spheres) differed significantly between treatment groups (side x region x treatment interaction p < 0.025). In the control group, major improvement was found only in con tralateral cerebrum (7.4%), whereas the nimodipine group had bilaterally increased rCMRglc of morphologically in tact cerebral (14.6 and 17.1%, respectively) and, to a lesser degree, cerebellar (6.9 and 10.0%, respectively) structures. Likewise, progress of (postacute) rehabilita tion was significantly (PI < 0.05) better in the nimodipine treated patients (median change of Barthel Index = 40 vs. 2.5), although their clinical improvement during the first 3 weeks did not differ from the controls' (median change of Mathew Score = 12 and 1l.5, respectively). These re sults lend further support to the notion that nimodipine treatment is of benefit in acute ischemic stroke. Since action on the infarct proper is unlikely when the drug is given many hours after the ischemic attack, it may be concluded that nimodipine exerts its beneficial effect by ameliorating the functional impairment of morphologi cally intact tissue surrounding the focal ischemia and by improving the metabolic deactivation of remote brain structures. Key Words: Glucose metabolism Nimodipine-Positron emission tomography-Stroke. cell damage following ischemia (review in Heiss, 1988) . Specific treatments so far have been disap pointing, since the time window during which im provement of flow could save nerve cells is usually much shorter than clinical practice permits. Like wise, measures intended to prolong the tolerance to ischemia must be installed during this short time interval. Therefore, several strategies recently fo cused on the biochemical sequelae of ischemia that intensify and prolong neuronal loss even when some perfusion could be reinstalled (Siesj6 and Wieloch, 1985) .
One of the mechanisms contributing to secondary ischemic cell damage is an increase of the intracel lular Ca 2+ concentration (Siesjo, 1981) ; conse quently, the decrease of Ca 2 + entry by Ca 2 + chan nel blockers, e.g., nimodipine, was shown to reduce histologic brain damage and to improve neurologic defects in animal experiments (Steen et aI., 1984; Mohamed et aI., 1985; Sauter and Rudin, 1986; Ger mano et aI., 1987) . A recent placebo-controlled dou ble-blind multicenter study of nimodipine in acute ischemic stroke (Gelmers et aI., 1988 ) demonstrated significant improvement in mortality and in neuro logic outcome of the treated group. However, a quantification of the extent of brain damage was not attempted in that study.
As morphologic integrity and functional activity of the tissue are related to local cerebral blood flow and metabolism, e.g., the local CMR g lc, positron emission tomography (PET) of 2-[ ,8 F] fluoro-2-deoxY-D-glucose (FDG) may allow estimation of the size of infarction, the severity of neuronal dam age in surrounding tissue, and the extent of deacti vation in remote brain regions.
Therefore, it was the aim of this study to assess differences in permanent morphologic and func tional damage between nimodipine-and placebo treated patients with acute ischemic stroke.
METHODS

Patient selection
According to the protocol approved by the Ethics Com mittee of the Medical Faculty of the University of Co logne, patients of either sex who met the following crite ria qualified for entry into the study: age above 45 years, acute completed ischemic stroke, and admission to the University Hospital Neurology Department within 48 h after onset of symptoms. The diagnosis of acute ischemic stroke was based on a typical history confirmed by a complete neurologic workup including a computed to mography (CT) scan. All patients with neurologic signs and symptoms caused by factors other than ischemia due to atherothrombosis, such as subarachnoid hemorrhage, intracerebral hematoma, complicated migraine, trauma, or tumor, were excluded. Patients with overt, severe sys temic disease (e.g., recent myocardial infarction, persis tent cardiac arrhythmia or circulatory insufficiency, se vere renal or hepatic failure, severe systemic infection, and nonstabilized diabetes mellitus), comatose patients, and those with previous cerebral infarction were also ex cluded. None of the patients was on aspirin or heparin treatment. Written informed consent to the study was obtained from the patient whenever possible and/or from the next of kin.
Clinical assessment on admission and after 3 weeks of treatment used the Mathew Score (Mathew et aI., 1972) ; for a patient to be eligible, the initial score had to be <66. The Barthel Index (Mahoney and Barthel, 1965) was as sessed 21 days and 6 months after initiation of treatment. FDG PET was performed on the day of admission. In all J Cereb Blood Flow Metab. Vol. 10. No. I, 1990 cases, it was completed within 48 h of the first stroke symptoms. FDG PET was repeated after 21 days of ther apy.
Treatment regimen and drug administration
If all requirements for entry into the study, including performance of CT and FDG PET, were met, the patients were randomly assigned to either a control or a treatment group that was initiated no later than 48 h after the attack. All patients remained in the neurologic intensive care unit for at least 1 week. They received a treatment including low molecular weight dextran (500 mllday for 14 days) and antiedematous infusions (10% glycerol solution for 5 days). Electrolytes and fluids were substituted, metabolic abnormalities (especially moderate hyperglycemia) were corrected, hypertension was controlled at systolic values below 170 mm Hg, and moderate transient cardiologic problems were treated. If necessary, patients were se dated. In the treatment group, nimodipine was given in addition to the mentioned treatment, while the patients in the control group received carrier solution and placebos subjectively indistinguishable from the treatment. In both groups, identical tubing and protective measures were used. To ensure double-blind conditions, nimodipine or placebo/carrier for each patient was packed in a box iden tified only by a random number. All prepackaged study materials were supplied by Bayer Co. (Leverkusen, F.R.G.).
The starting dose of nimodipine was I mg/5 ml/h, and after the first 2 h the infusion rate was adjusted at 2 mg/IO mllh. Only in two control cases did the increase in dosage cause a drop in blood pressure, and the dose had to be decreased again to 1 mg/5 mllh. After 5 days of constant infusion of 2 mg/IO mllh nimodipine or the corresponding amount of nimodipine-free carrier, treatment was contin ued orally with 1 tablet four times daily, with each con taining 30 mg nimodipine or placebo. Treatment ended after 21 days.
FDG PET studies
Before initiation and after termination of the 21-day treatment period, the regional CMRglc (rCMRg1c) was studied with FDG and PET (Reivich et aI., 1979) , using a four-ring positron camera (Scanditronix PC384) simulta neously scanning seven slices (Il-mm thickness) at an in-slice spatial resolution of 7.8 mm full width at half maximum (Eriksson et aI., 1982) . After careful position ing by means of laser beams and skin marks, studies were performed, with patients resting in a darkened room with low ambient noise, eyes closed and ears unoccluded.
One hundred eighty-five megabecquerels (5 mCi) FDG [synthesized according to the method of Ehrenkaufer et al. (1984) ] was injected intravenously. Investigative and scanning procedures as well as image processing were performed as elsewhere described in detail (Heiss et aI., 1984) . CMRglc in the 14 equally spaced (center-to-center distance 6.9 mm) slices scanned in parallel with the can thomeatal line between 30 and 50 min after FDG injection was calculated using a fixed value of 0.42 for the lumped constant and rate constants adjusted for the measured tissue activities according to a KCk3 optimization proce dure (Wienhard et aI., 1985) requiring less stringent as sumptions about the tracer behavior in abnormal tissue. No additional correction was applied to adjust for possi ble changes of the lumped constant in the infarcted area (Gjedde et aI., 1985) . In all cases, the images showed the brain from the lowest cerebellar level to the top of the oval center. Standardized regional quantitation was achieved using an interactive mapping program (Herholz et aI., 1985) . Careful patient repositioning in the camera by means of laser beams and skin marks in conjunction with a categorical region matching and block shifting pro cedure (Pawlik et aI., 1986) provided optimal comparabil ity both among subjects and between paired data of the same patient. Briefly, the latter procedure first assessed the congruence between paired sets of standardized re gions of interest according to region names and slice po sitions, using Tanimoto coefficients to describe their de gree of similarity. By separately shifting upward and downward in single-slice steps the stacks of frontal, mid dle, and occipital regions, eventually the position of max imum anatomical correspondence was found. The algo rithm was then applied again to match the intersection of the paired region sets to a reference set obtained from PET studies of healthy subjects. Only the regions com mon to all sets after shifting were used in further analy ses.
Statistical methods
Descriptive statistics are presented either as means ± SD or as medians (minimum-maximum), depending on the nature of the data, i.e., whether they were actual measurements or rating scores. Likewise, in univariate two-sample comparisons, either one-way analysis of vari ance (ANOY A) or the rank sum test was used. Unless clearly appropriate for the problem under investigation and specifically indicated by subscript (PI)' all statistical tests were two entailed. p values of >0.10 are reported as being not significant. Contingency tables were analyzed by means of Fisher's (e.g., sex x treatment) or Freeman Halton's (e.g., infarct location x treatment) exact tests. After testing for normality and homoscedasticity, statis tical assessment of starting values and treatment effects on rCMRglc and of potential hemispheric or regional dif ferences was performed by repeated-measures ANOY A (Pawlik, 1988) , with one grouping factor (treatment) in teracting with the within factors region (infarct or mirror, cerebral gray matter, cerebellum) and side (affected and "unaffected" hemisphere). The heterogeneous interde pendence among concurrently measured regional data was accounted for by decreasing the degrees of freedom of the critical F value according to the method of Huynh and Feldt (1976) . Orthogonal post-hoc contrasts were used only for explaining significant overall effects involv ing the three-level region factor.
RESULTS
Twenty-seven consecutive patients eligible for in clusion in the study were randomly assigned to ei ther treatment. All suffered from marked neurologic deficits due to uniformly distributed ischemic in farctions in the territory of one middle cerebral ar tery. Without any obvious relation to treatment, the four patients with total infarct of the middle cere bral artery died during the first 3 weeks after their stroke and therefore could not be evaluated. When the code was revealed, three of these cases turned out to belong to the nimodipine and one to the con trol group. The remaining 23 patients completed the main phase of the study (3 weeks and second PET study), showing no treatment-related side-effects. During the follow-up period of 6 months after their stroke, another three placebo-treated and two ni modipine-treated patients died. After completion of the total observation period, the code was broken, and the patients were divided into control and ni modipine groups, for further analysis. Table 1 shows the clinical summary data of the two groups, listing starting averages and changes with time in relation to the initial findings. The Barthel Index at the end of drug treatment was somewhat lower (p = 0.10) in the nimodipine group. However, that group showed the larger trend toward subsequent im provement (PI < 0.05). No significant differences between the two groups were found for any of the other clinical variables, i.e., age and sex distribu tion, neurologic deficit (initial Mathew Score and its change during treatment), and infarct size and loca tion.
In the initial FDG PET studies, all patients ex- hibited a region with extremely low rCMR g Ic, rep resenting the infarction as outlined on x-ray CT. Additionally, regions with graded decreases of CMR g Ic surrounded the infarct proper, and subnor mal rCMR g Ic in the ipsilateral hemisphere and in the contralateral cerebellum indicated functional deac tivation. Both the initial whole-brain CMR g lc (con tro128.4 ± 3.16 j.Lmol J lOO g/min; nimodipine 27.1 ± 2.87 j.Lmol/IOO g/min) and its change during the 3week treatment period (control 2.5 ± 2.64 j.Lmol l lOO g l min; nimodipine 4.5 ± 3.01 j.Lmol l l00 g/min) were similar in the two groups. For regional analysis, rCMR g Ic values representing the infarct, nonin farcted ipsilateral cerebral gray matter (cortex, basal ganglia, thalamus), and contralateral cerebel lum ("affected side") as opposed to the values in the "unaffected side" (area contralateral to infarc tion, other gray matter of the contralateral cerebral hemisphere, ipsilateral cerebellum) were compared in the two groups. As demonstrated in Table 2 pre senting the initial values and changes of rCMR g Ic for these regions, the two groups were quite similar with respect to their initial metabolic depression. While changes in the infarct area were not different, rCMR g Ic in noninfarcted regions increased more in the nimodipine than in the control group. This dif ferential regional effect of nimodipine on glucose metabolic changes was proven by repeated measures ANOVA (p < 0.025 for triple interaction of side x region x treatment). According to post hoc interaction contrasts for infarct versus cerebral gray matter plus cerebellum and for cerebral gray matter versus cerebellum, it was due mainly to the greater improvement in the nimodipine group of ip silateral cerebral gray matter and of the infarct mir ror region.
DISCUSSION
Despite small sample sizes, this controlled dou ble-blind study demonstrated a significant benefi cial effect of nimodipine treatment on glucose me tabolism of noninfarcted brain regions and on long term rehabilitation in patients with acute ischemic stroke, thus corresponding with the clinical efficacy recently observed in a large clinical trial (Gelmers et aI., 1988) .
When analyzing these results, it should be em phasized that treatment was initiated late after the ischemic insult: Typically, the patient suffers the ischemic attack at home, often at night, and it takes time until he/she is seen by a doctor and admitted to a hospital. Until diagnostic procedures are conclu sive and specific treatment can be initiated, many hours may pass, and ischemic cell damage usually has advanced far beyond the therapeutic window during which increases of local perfusion or im provements of the cells' tolerance to ischemia could affect the developing necrosis. Only in regions sur rounding the core of dense ischemia, where flow may be decreased to values below those necessary for maintenance of brain function but still hovering above the threshold for preservation of morpho logic integrity [the "ischemic penumbra" according to Astrup et al. (1981) ), and in areas where neurons are suffering from metabolic sequelae of transient Initial NS p = 0.0001 NS p = 0.0001 NS P = 0.0003 NS Change NS p = 0.005 NS p = 0.040 NS NS p = 0.022 ischemia finally leading to cell death ["delayed neu ronal death" according to Kirino (1982) ] could treatment initiated after the first few hours help to limit the developing brain infarction. In animal ex periments it was shown repeatedly that Ca 2+ chan nel blockers, e.g., nimodipine, can reduce cellular damage in the periphery of an ischemic lesion (Mo hamed et aI., 1985; Gotoh et aI., 1986) and diminish the extent of infarction (Sauter and Rudin, 1986) , and that this drug is also effective when given after ischemia (Steen et aI., 1984 (Steen et aI., , 1985 . A causal rela tionship between the beneficial neurologic course and an effect on postischemic hypoperfusion (Milde et aI., 1986 ) appears rather unlikely, since improve ments were also observed without effects on blood flow (Smith et aI., 1983; Gotoh et aI., 1986; Berger and Hakim, 1988) . For nimodipine to have a bene ficial effect on the cell damage following an isch emic insult, it may be of greater import to accelerate the restoration of high-energy phosphates (Bielen berg et aI., 1987) and to correct cerebral acidosis (Hakim, 1986; Meyer et aI., 1986; Berger and Hakim, 1988) .
The negligible metabolic change of the infarcted region observed with both nimodipine and standard treatment may be explained in this context. Given many hours after the ischemic insult, nimodipine can hardly help cells in this region to survive while blood flow and the cerebral metabolic rate of oxy gen are depressed, as shown in a recent PET study (Hakim et aI., 1989) . The clinically relevant effects take place in noninfarcted but functionally impaired tissue: Hakim et aI. (1989) observed improvements of oxygen consumption and extraction in the pen umbra zone (defined as cortical regions in the prox imity of the infarct and perfused at flow values be tween 12 and 18 ml l lOO g/min). With improved me tabolism, more cells in these regions can survive and, as demonstrated in our study, glucose metab olism reaches higher values on later measurements.
A second mechanism by which nimodipine given after the ischemic attack could improve the clinical course is suggested by the present results. Meta bolic deactivation in morphologically intact brain structures remote from a focal flow disturbance is a constant finding with PET (Baron et aI., 1980; Kuhl et aI., 1980; Kushner et aI., 1984; Pawlik et aI., 1985; Feeney and Baron, 1986) . The extent of this functional deactivation has some influence on the occurrence of more generalized deficits, e.g., im pairment of consciousness, disturbance of cognitive and memory function, and also on the patient' s prospects for rehabilitation. An effect of nimodipine on glucose metabolism of remote brain structures, therefore, may be related to a more favorable long-term clinical outcome, as demonstrated in this study.
In conclusion, our PET findings suggest that the recently reported beneficial effect of nimodipine treatment in acute ischemic stroke (Gelmers et aI., 1988) , which was also confirmed in this study, may be ascribed to some drug action on functionally im paired but morphologically intact tissue in the neighborhood of infarction and on functionally de activated brain structures remote from the focal ischemic lesion. When given hours after the attack, necrosis in the ischemic center cannot be influ enced. Improved metabolism in other tissue com partments, however, can ameliorate secondary cell loss and improve the patient' s functional prognosis.
